Etelcalcetide
 | |
| Clinical data | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | 1262780-97-1 |
| Synonyms | Velcalcetide, AMG 416, KAI 4169, ONO 5163, Telcalcetide |
| Chemical data | |
| Formula | C38H73N21O10S2 |
| Molar mass | 1,048.26 g·mol−1 |
Etelcalcetide is a D-amino peptide calcimimetic undergoing clinical evaluation for the treatment of secondary hyperparathyroidism for patients with chronic kidney disease (CKD) on hemodialysis. Etelcalcetide is administered intravenously at the end of each dialysis session.[1][2] It functions by binding to and activating the calcium-sensing receptor (CaSR) in the parathyroid gland as an allosteric activator, resulting in PTH reduction and suppression.[1] Elevated PTH is often observe in patients with CKD.[3]
On August 25, 2015 Amgen Inc. announced its submission of a New Drug Application to the Food and Drug Administration for etelcalcetide.[1]
References
- 1 2 3 "Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)”
- ↑ "Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
- ↑ "Evidence for Chronic Kidney Disease-Mineral and Bone Disorder Associated With Metabolic Pathway Changes”
Further reading
This article is issued from Wikipedia - version of the Saturday, September 12, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.